Sign in

    Chris

    Managing Director at Baird

    Chris Coetzee is a Managing Director at Baird, leveraging over three decades of investment banking experience to deliver financing and advisory services across a wide range of sectors. Joining Baird in 1994, he has played a pivotal role in transactions for numerous middle-market companies, guiding clients through mergers, acquisitions, and capital-raising initiatives. Throughout his distinguished career, Chris has become recognized for his expertise in deal execution and client service, contributing to Baird's reputation as a leading platform for institutional equities and investment banking. He maintains strong professional credentials reflecting his extensive background in the industry.

    Chris's questions to Axsome Therapeutics (AXSM) leadership

    Chris's questions to Axsome Therapeutics (AXSM) leadership • Q1 2025

    Question

    Chris, on behalf of Joel Beatty from Baird, asked about Axsome's plans for the recent SYMBRAVO data in CGRP non-responders, specifically if it would be pursued as a new indication or label expansion. He also inquired about the status of pursuing a label expansion for SYMBRAVO in adolescents.

    Answer

    Ari Maizel, CCO, explained that while the CGRP data is compelling for clinicians, the company is not currently seeking to add it to the label as a new indication but will communicate the data through medical affairs and compliant promotional activities. Mark Jacobson, COO, confirmed that the pediatric development work for SYMBRAVO is underway as agreed with the FDA.

    Ask Fintool Equity Research AI